306 related articles for article (PubMed ID: 21200420)
1. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Machado PR; Ampuero J; Guimarães LH; Villasboas L; Rocha AT; Schriefer A; Sousa RS; Talhari A; Penna G; Carvalho EM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e912. PubMed ID: 21200420
[TBL] [Abstract][Full Text] [Related]
2. Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial.
Prates FV; Dourado ME; Silva SC; Schriefer A; Guimarães LH; Brito MD; Almeida J; Carvalho EM; Machado PR
Clin Infect Dis; 2017 Jan; 64(1):67-71. PubMed ID: 27803094
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
4. A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.
Machado PRL; Prates FVO; Boaventura V; Lago T; Guimarães LH; Schriefer A; Corte TWF; Penna G; Barral A; Barral-Netto M; Carvalho EM
Clin Infect Dis; 2021 Oct; 73(7):e2465-e2469. PubMed ID: 32894278
[TBL] [Abstract][Full Text] [Related]
5. Interventions for American cutaneous and mucocutaneous leishmaniasis.
Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410
[TBL] [Abstract][Full Text] [Related]
6. Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis.
Brito G; Dourado M; Guimarães LH; Meireles E; Schriefer A; de Carvalho EM; Machado PRL
Am J Trop Med Hyg; 2017 May; 96(5):1155-1159. PubMed ID: 28500815
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
8. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
9. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.
Soto J; Rojas E; Guzman M; Verduguez A; Nena W; Maldonado M; Cruz M; Gracia L; Villarroel D; Alavi I; Toledo J; Berman J
Clin Infect Dis; 2013 May; 56(9):1255-60. PubMed ID: 23390069
[TBL] [Abstract][Full Text] [Related]
10. Oral miltefosine to treat new world cutaneous leishmaniasis.
Soto J; Toledo JT
Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
[No Abstract] [Full Text] [Related]
11. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.
Peixoto F; Nascimento MT; Costa R; Silva J; Renard G; Guimarães LH; Penna G; Barral-Netto M; Carvalho LP; Machado PRL; Carvalho EM
J Immunol Res; 2020; 2020():2789859. PubMed ID: 32851099
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
14. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
[TBL] [Abstract][Full Text] [Related]
15. Miltefosine Combined with Intralesional Pentamidine for
Soto J; Soto P; Ajata A; Rivero D; Luque C; Tintaya C; Berman J
Am J Trop Med Hyg; 2018 Nov; 99(5):1153-1155. PubMed ID: 30255833
[TBL] [Abstract][Full Text] [Related]
16. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Soto J; Toledo J; Valda L; Balderrama M; Rea I; Parra R; Ardiles J; Soto P; Gomez A; Molleda F; Fuentelsaz C; Anders G; Sindermann H; Engel J; Berman J
Clin Infect Dis; 2007 Feb; 44(3):350-6. PubMed ID: 17205440
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
Ventin F; Cincurá C; Machado PRL
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis.
Kämink S; Masih B; Ali N; Ullah A; Khan SJ; Ashraf S; Pylypenko T; Grobusch MP; Fernhout J; den Boer M; Ritmeijer K
PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008988. PubMed ID: 33507944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
